Canada

Delmar Chemicals Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

DelMar Announces $19.6 Million Private Placement Priced at-the-Market

Lead Product(s): Dianhydrogalactitol

Therapeutic Area: Oncology Product Name: VAL-083

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $19.6 million Upfront Cash: Undisclosed

Deal Type: Private Placement August 18, 2020

Details:

Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme, the 15-patient REM-001 confirmatory lead-in study and for working capital.

Sierra Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

Lead Product(s): Momelotinib

Therapeutic Area: Oncology Product Name: GS-0387

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 06, 2020

Details:

Mr. Kevin Norrett will support Sierra's MOMENTUM Phase 3 trial and delivering a high-quality outcome that may enable momelotinib's global registration.

Sierra Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

Lead Product(s): Momelotinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2020

Details:

Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib.

Orion Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Orion Receives Total of EUR 28 Mllion Milestones From Bayer For Sales of Darolutamide

Lead Product(s): Darolutamide

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Bayer HealthCare

Deal Size: $31.3 million Upfront Cash: Undisclosed

Deal Type: Agreement May 20, 2020

Details:

The transaction follows the Sales of Nubeqa® (darolutamide), jointly developed by Orion Corporation and Bayer for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), started in the EU and Japan.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Delmar Chemicals Inc.

DelMar Announces $19.6 Million Private Placement Priced at-the-Market

Sierra Oncology

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

Sierra Oncology

Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

Orion Biotechnology

Orion Receives Total of EUR 28 Mllion Milestones From Bayer For Sales of Darolutamide